ruxolitinib and tofacitinib are similar, very new biologic agents which show very great effects in AA/AT/AU. The problems are (1) Huge cost - this inevitably comes down when new drugs arrive to compete and when the drug's patent expires [usually about 10 yrs] (2) New drugs = no great experience yet of side effects - time will tell how safe they are (3) Thus far, used orally - when we would all prefer something applied to the surface, hey?
Nonetheless, these drugs are the first two in an entirely new class - and ruxolitinib is the first ever drug being specifically developed for AA/AT/AU patients.
I am cautiously optimistic!
To see the results of the trials, look here: